Exencial Wealth Advisors LLC Buys New Stake in EXACT Sciences Co. (EXAS)

Exencial Wealth Advisors LLC bought a new position in EXACT Sciences Co. (NASDAQ:EXAS) during the first quarter, according to the company in its most recent filing with the SEC. The firm bought 4,082 shares of the medical research company’s stock, valued at approximately $354,000.

Other large investors have also modified their holdings of the company. Cerity Partners LLC bought a new stake in EXACT Sciences in the 4th quarter worth $260,000. Lisanti Capital Growth LLC bought a new stake in EXACT Sciences in the 4th quarter worth $720,000. Bronfman E.L. Rothschild L.P. grew its holdings in EXACT Sciences by 13.3% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 5,301 shares of the medical research company’s stock worth $334,000 after acquiring an additional 621 shares during the last quarter. GSA Capital Partners LLP bought a new stake in EXACT Sciences in the 4th quarter worth $300,000. Finally, Meeder Asset Management Inc. grew its holdings in EXACT Sciences by 602.9% in the 4th quarter. Meeder Asset Management Inc. now owns 2,910 shares of the medical research company’s stock worth $184,000 after acquiring an additional 2,496 shares during the last quarter.

In related news, Director Katherine S. Zanotti sold 25,000 shares of the business’s stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $92.81, for a total transaction of $2,320,250.00. Following the sale, the director now owns 94,274 shares of the company’s stock, valued at $8,749,569.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin T. Conroy sold 11,227 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $87.21, for a total transaction of $979,106.67. Following the sale, the insider now directly owns 949,753 shares in the company, valued at approximately $82,827,959.13. The disclosure for this sale can be found here. Insiders have sold 60,201 shares of company stock worth $5,543,493 in the last three months. 3.20% of the stock is currently owned by insiders.

Shares of EXAS opened at $94.91 on Thursday. EXACT Sciences Co. has a 1-year low of $47.78 and a 1-year high of $105.28. The company has a debt-to-equity ratio of 1.02, a quick ratio of 8.13 and a current ratio of 8.39. The stock has a market cap of $12.52 billion, a PE ratio of -69.79 and a beta of 1.84.

EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.01). EXACT Sciences had a negative return on equity of 28.83% and a negative net margin of 41.58%. The business had revenue of $162.00 million for the quarter, compared to the consensus estimate of $153.07 million. During the same period in the previous year, the firm earned ($0.33) EPS. The company’s revenue was up 79.4% on a year-over-year basis. Research analysts expect that EXACT Sciences Co. will post -2.13 EPS for the current year.

EXAS has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of EXACT Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, February 13th. UBS Group lifted their target price on shares of EXACT Sciences from $109.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, April 16th. Robert W. Baird lifted their target price on shares of EXACT Sciences from $90.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, February 21st. BTIG Research lifted their target price on shares of EXACT Sciences to $110.00 and gave the company a “positive” rating in a research note on Friday, February 22nd. Finally, Goldman Sachs Group raised shares of EXACT Sciences from a “neutral” rating to a “buy” rating and lifted their target price for the company from $85.00 to $120.00 in a research note on Tuesday, February 26th. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $108.45.

ILLEGAL ACTIVITY WARNING: “Exencial Wealth Advisors LLC Buys New Stake in EXACT Sciences Co. (EXAS)” was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/23/exencial-wealth-advisors-llc-buys-new-stake-in-exact-sciences-co-exas.html.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

See Also: Is it Safe to Invest in Commodities?

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.